The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Nanocarriers as an emerging platform for cancer therapy
Abstract
Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, their capability to co-delivering therapeutics and diagnostic reagents, which have greatly promoted the development of theranostics and smart nanoparticles for cancer therapy.13”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [13]
In the citing paper
“In contrast to easily diffusible free drugs, a nanocarrier can penetrate into the tumor tissue through the leaky vasculature due to the enhanced permeation and retention effect.225”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [225]
In the citing paper
“Meanwhile, many types of ligands, such as folate, transferrin, antibody and aptamer, etc., can also be incorporated into the non-viral vectors to boost cellular uptake via receptor-mediated endocytosis [171–173].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [172]
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance
Hirsch, L. R., Stafford, R. J., Bankson, J. A., Sershen, S. R., Rivera, B., Price, R. E., Hazle, J. D., Halas, N. J., & West, J. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232479100 · Cited by 3,961
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,040
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,389
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. I. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,040
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1958 · Cited by 1,956
Research works printed but not linked: 2
- James, J. S. & Dubs, G. FDA approves new kind of lymphoma treatment. AIDS Treat. News 284, 2–3 (1997).
- Kontermann, R. E. Immunolliposomes for cancer therapy. Curr. Opin. Mol. Ther. 8, 39–45 (2006).
Cited by
Sorted by citations
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationAnalysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Clinical development and potential of photothermal and photodynamic therapies for cancer
Li, X., Lovell, J. F., Yoon, J., & Chen, X. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0410-2 · Cited by 3,456
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Self-citationSahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Metadata
- Authors
- Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Massachusetts Institute of Technology (US)
- Tel Aviv University (IL)
- Venue
- Nature Nanotechnology
- Published
- 2007-12
- Volume
- 2
- Issue
- 12
- Pages
- 751-760
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W2032760352
- Cited by
- 8,710
- References
- 106
- Citations by year
- 2026: 315 · 2025: 354 · 2024: 357 · 2023: 383 · 2022: 454 · 2021: 563 · 2020: 618 · 2019: 607 · 2018: 686 · 2017: 677 · 2016: 659 · 2015: 664 · 2014: 600 · 2013: 536 · 2012: 453
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Nanotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u54ca119349-05)
- National Cancer Institute (CA 119349)
- National Institute of Biomedical Imaging and Bioengineering (K08EB003647, R01EB000244, EB003647)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- nanocarriers, cancer therapy, tumor targeting, targeted drug delivery, clinical translation, nanomedicine, cancer diagnosis
- MeSH terms
- Antineoplastic Agents, Drug Carriers, Drug Compounding, Neoplasms, Nanostructures, Nanomedicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
